Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

CAMP4 Therapeutics Corp

CAMP ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$4.45

▲ +3.01%

Market Cap $279.25M · Vol 76.49K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$279.25M

Micro Cap

Div Yield

N/A

EPS Growth

+58.44%

YoY

RSI (14)

56.40

Momentum

Beta

N/A

vs Market

52W High

$7.74

42.51% below

52W Low

$1.41

215.60% above

Volume

76.49K

Avg 54.44K

P/B

6.67

Price-to-book

ROE

-145.07%

Return on equity

Free Float

88.32%

Public shares

Shariah Compliance8 STANDARDS

✗ CAMP4 Therapeutics Corp (CAMP) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CAMP pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-9.18%

+40.82%

-1.33%

+0.00%

YTD

-27.41%

+185.26%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$3.50M
Net Income	$-80,403,000.00
Revenue Growth (YoY)	+18.84%
Gross Margin	100.00%
Operating Margin	-1,488.31%
Net Profit Margin	-2,298.54%
ROE	-145.07%
ROA · ROIC	-82.00% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	53.24
P/B	6.67
P/FCF	N/A
EPS Growth	+58.44%
Outstanding Shares	62.75M

Technical Indicators

50-Day SMA	$4.12
200-Day SMA	$4.49
RSI (14)	56.40
Beta	N/A
52-Week High	$7.74
52-Week Low	$1.41

Volume Today	76.49K
Avg Daily Volume (30D)	54.44K
Relative Volume	1.41x
Volatility (10D)	119.05
Volatility (30D)	114.20
Free Float	88.32%

Analyst Consensus

BUY

Current Price $4.45

Mean Target $10.10

52W Low$1.41 52W High$7.74

Current

Target

$1.41 $7.74

Current Analyst target

+126.97% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00L2CHQ99

ISINUS13463J1016

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.02% ONC BeOne Medicines AG +1.18% RVMD Revolution Medicines Inc -0.09% 068270.KS Celltrion Inc -2.27% ABVX Abivax SA +1.53%

Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.